Ani pharmaceuticals announces the launch of kionex® suspension

Baudette, minn., may 20, 2024 (globe newswire) -- ani pharmaceuticals, inc. (ani or the company) (nasdaq: anip) today announced the launch of kionex® (sodium polystyrene sulfonate suspension usp) for oral or rectal use. kionex® suspension is the only commercially available therapeutically equivalent to the reference listed drug (rld) sps® suspension for oral or rectal use.

ANIP Ratings Summary

ANIP Quant Ranking